natgillin/translations-raw huggingface dataset:
the obtained compound of formula (II) is converted into a salt or the obtained salt of the compound of formula (II) is converted to the compound of formula (II). 
dobiveni spoj formule (II) se prevede u sol ili se dobivenu sol spoja formule (II) prevede u spoj formule (II).
A mutant G-protein coupled receptor (GPCR) with increased conformational stability compared to its parent GPCR, which mutant GPCR has an extended lifetime of a particular conformation relative to the same conformation of its parent GPCR under denaturing conditions, the extended lifetime being manifest by retention of ligand binding ability. 
određivanje je li ta ili svaka mutacija GPCR-a povećala konformacijsku stabilnost u odnosu na vezanje odabranog liganda u usporedbi s konformacijskom stabilnosti izvornog GPCR-a u odnosu na sposobnost vezanja tog liganda, i to na temelju mjerenja denaturacije koja se očituje gubitkom sposobnosti vezanja liganada, pod uvjetima denaturacije kao što su zagrijavanje, deterdžent, kaotrop ili ekstremni pH, te
at least one compartment of an internal combustion engine that comprises used oil or at least one storage compartment comprising used oil, 
najmanje jednim odjeljkom 2 motora s unutrašnjim izgaranjem 1 koji sadrži rabljeno ulje ili najmanje jednim odjeljkom za pohranu koji sadrži rabljeno ulje,
The method according to claim 9 wherein the thrombolytic agent is a plasminogen activator. The method according to claim 9 wherein the thrombolytic agent is urokinase, streptokinase, alteplase or anistreplase. 
Upotreba prema bilo kojem zahtjevu 18 do 25, naznačena time, da farmaceutski sastav nadalje sadrži trombolitičko sredstvo, ponajprije aktivator plazminogena, urokinazu, streptokinazu, alteplazu ili anistreplazu.
The antibody or antigen binding fragment thereof of Claim 1 for use in the treatment of a disorder selected from the group consisting of multiple sclerosis, systemic lupus erythematosus and diabetes. The antibody or antigen binding fragment thereof of Claim 1 for use in the treatment of cancer. 
Antitijelo ili antigen vezujući fragment istog za upotrebu prema patentnom zahtjevu 9, za upotrebu u liječenju poremećaja odabranog iz grupe koja se sastoji od artritisa, psorijaze, inflamatorne bolesti crijeva, multiple skleroze, sistemskog eritemskog lupusa, dijabetesa i raka.
a group CH2R15, a heteroaryl group, optionally substituted with a C1-C6 alkyl group, or 
skupina CH2R15, heteroarilna skupina koja može biti supstituirana C1-C6 alkilnom skupinom ili
Determination of the Composition of Peptone Fractions 
Datum objave europskog patenta:
ATR number of individual tests 1.01 
(21) Broj predmeta:
Kit comprising the biologically active protein according to any one of claims 1 to 9, the nucleic acid according to claim 12, the vector according to claim 13 or the cell according to claim 14. 
Komplet, naznačen time što sadrži biološki aktivni protein u skladu s bilo kojim od patentnih zahtjeva 1 do 9, nukleinsku kiselinu u skladu s patentnim zahtjevom 12, vektor u skladu s patentnim zahtjevom 13 ili stanicu u skladu s patentnim zahtjevom 14.
Since the majority of hydrophobic groups are located in the core of globular proteins, the binding is related to the extent of denaturation of the protein and the accessibility of these groups to the column functional groups. 
Budući je većina hidrofobnih skupina locirana u unutrašnjosti globularnog proteina, vezivanje ovisi o stupnju denaturacije proteina te pristupačnosti spomenutih skupina funkcionalnim skupinama kolone.
An aqueous composition according to claims 1 to 13, comprising less than 40 ppb Ni based on the weight of the aqueous composition. 
Vodeni pripravak sukladno zahtjevima 1 do 13, koja sadrži manje od 40 ppb Ni temeljeno na težini vodenog pripravka.
This is contrary to the incompatibility detailed in the literature, e.g. in the Handbook of Pharmaceutical Excipients. 
Ovo je suprotno od inkompatibilnosti detaljno opisanoj u literaturi, npr., u Priručniku za farmaceutske inertne punitelje.
The analysis cartridge system of claim 11 wherein the fluorescence window (170) includes an outer surface, and wherein the outer surface of the fluorescence window is perpendicular to the outer surface of the light entry window (172a). 
Sustav kazete za analizu prema zahtjevu 11, naznačen time, da fluorescentni prozorčić (170) uključuje vanjsku površinu, te time, da je vanjska površina fluorescentnog prozorčića okomita na vanjsku površinu prozorčića za svjetlosni ulaz (1724).
The handgun holster according to claim 11, wherein attached to the lower part of the rear wall of the body of the holster is a delineative part which projects, with a spring-loaded tab part, into the cavity of the holster. The handgun holster according to claim 6, further comprising: 
Futrola prema bilo kojem patentnom zahtjevu od 1 do 10, naznačena time da pričvršćen na donji dio stražnje stijenke tijela (1) futrole nalazi se ocrtani dio (23) koji se sa svojim oprugom pritisnutim dijelom proteže u otvor futrole.
Another embodiment of the present invention relates to the above-mentioned method, wherein before the step of adding the Grignard reagent of the formula IX to the thiolactone of the formula VIII to obtain a compound V, about 0.8 to 1.2 equivalents of R30MgX (R30 represents a C1-8 alkyl group or a C3-7 cycloalkyl group, and X represents a halogen atom) is added to the thiolactone of the formula VIII. 
Postupak prema zahtjevu 26, naznačen time da se prije koraka dodavanja Grignardovog reagensa formule IX u tiolakton formule VIII da se dobije spoj V, oko 0.8 do 1.2 ekvivalenata R*MgX (R" predstavlja C.g alkil skupinu ili C3.; cikloalkil skupinu, te X predstavlja atom halogena) dodaje u tiolakton formule VIII.
The integrated circuit according to claim 1, wherein the mapping candidate is an EPDCCH candidate in the data region and consists of CCEs of an aggregation level, wherein the aggregation level indicates a number of CCEs that are aggregated to form one EPDCCH candidate. 
Komunikacijski postupak u skladu s jednim od zahtjeva 7 ili 8, naznačen time što je kandidat mapiranja kandidat Poboljšanog Fizičkog Kontrolnog Kanala Silazne Veze, EPDCCH, u području podataka i sastoji se od CCE-ova istog broja kao i vrijednost razine agregacije.
Thus, it is possible to put the packaging into a conventional packing machine for packing it. FIG. 
Na taj je način moguće staviti pakiranje u konvencionalni stroj za pakiranje radi obavljanja njegovog pakiranja.
mutating at least two amino acid positions selected for mutation, 
(A) odabiranje najmanje tri aminokiselinske pozicije unutar
wherein the filter is applied to the intra prediction mode having the direction of 45° with respect to the horizontal mode and is not applied to the horizontal mode and a vertical mode, 
Uređaj iz zahtjeva 1, pri čemu, kada je filter primjenjen na intrapredikcijski režim sa smjerom od 45° u odnosu na horizontalni režim i kada nije primjenjen na horizintalni režim i vertikalni režim.
wherein R17 represents hydrogen or fluorine, p represents 1 or 2 and X represents O or S; 
X-CH = N-; gdje R'" predstavlja vodik ili fluor, p predstavlja 1 ili 2 i X predstavlja O ili S;
3, with at least one of the mutations selected from the group consisting of amino acid Q at position 1 being replaced by E, amino acid V at position 11 being replaced by L, amino acid G at position 42 being replaced by K, amino acid S at position 50 being replaced by V, amino acid Y at position 53 being replaced by S, amino acid K at position 58 being replaced by T, amino acid G at position 61 being replaced by A, amino acid S at position 75 being replaced by T, amino acid K at position 76 being replaced by R, amino acid N at position 77 being replaced by S, and amino acid T at position 78 being replaced by N, and/or wherein the light chain variable region comprises the amino acid sequence shown in SEQ ID NO. 
3, gdje se najmanje jednu od mutacija bira iz skupine koju čine aminokiselina Q na položaju 1, zamijenjena s E, aminokiselina V na položaju 11, zamijenjena s L, aminokiselina G na položaju 42, zamijenjena s K, aminokiselina S na položaju 50, zamijenjena s V, aminokiselina Y na položaju 53, zamijenjena s S, aminokiselina K na položaju 58, zamijenjena s T, aminokiselina G na položaju 61, zamijenjena s A, aminokiselina S na položaju 75, zamijenjena s T, aminokiselina K na položaju 76, zamijenjena s R, aminokiselina N na položaju 77, zamijenjena s S, te aminokiselina T na položaju 78, zamijenjena s N, i/ili gdje varijabilno područje lakog lanca sadrži aminokiselinski slijed prikazan u SEQ ID NO.
The method of claim 29, wherein the condition is cancer of the uterine cervix, oropharynx, anus, anal canal, anorectum, vagina, vulva, or penis. 
rak vrata maternice, orofarinksa, anusa, analnog kanala, anorektuma, vagine, vulve ili penisa; ili rak pozitivan na HPV 16.
The IL-2 was precipitated by addition of sodium hydroxide (NaOH) and collected by centrifugation. 
IL-2 je istaložen dodavanjem natrijevog hidroksida (NaOH) i sakupljen pomoću centrifugiranja.
The composition of aspect 1, wherein the carbohydrate is present in an amount sufficient to increase the stability of the protein. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna za povećanje stabilnosti proteina.
The phases were separated and the organic layer was evaporated to give the title compound (2.3 g, 100%) as a yellow oil which was a mixture of diastereomers. 
Faze se razdvoji, a organski sloj otpari kako bi se dobilo naslovni spoj (2,3 g, 100 %) u obliku žutog ulja, koje je smjesa dijastereomera.
The fusion protein of claim 1 or claim 2, wherein the fusion protein binds to growth hormone receptor(s) with a reduced binding affinity compared to that of the corresponding GH that lacks the XTEN, wherein the binding affinity is optionally reduced by at least about 10-fold. 
Fuzijski protein prema zahtjevu 1 ili zahtjevu 2, naznačen time, da se fuzijski protein veže na receptor/e hormona rasta sa smanjenim afinitetom vezanja u usporedbi s onim od odgovarajućeg GH kojemu nedostaje
Pharmaceutical composition according to any one of claims 1-3 for use in treating pathologies affecting the urogenital system, the endocrine system, the skin and/or the cutaneous appendages. 
Korteksolon-17a-propionat u kristalnom obliku I u skladu s bilo kojim od patentnih zahtjeva 17 do 18, naznačen time što je namijenjen upotrebi u liječenju patoloških pojava koje pogađaju urogenitalni sustav, endokrini sustav, kožu i/ili kožne adnekse.
The antibody according to item 2, wherein the cytotoxic activity is an antibody-dependent cell-mediated cytotoxic activity (ADCC activity). 
Farmaceutski pripravak prema zahtjevu 1, naznačen time, što citotoksično djelovanje predstavlja stanično posredovano citotoksično djelovanje ovisno o antitijelu (engl. antibody-dependent cell-mediated; ADCC djelovanje).
A composition according to any one of the preceding claims wherein the (S)-2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol is in the form of a free base or an acid addition salt. 
Pripravak prema bilo kojem od prethodnih zahtjeva naznačen time da je (S)-2-amino-1-(4-klorlo-fenil)-1-[4- (IHpirazol-4-11)-fenil]-etanol u obliku aditivne soli neke slobodne baze ili kiseline.
treating said skin condition to actinic light for a time sufficient for said photoactivator to cause oxidation of said oxidant. The composition according to claim 1, wherein said skin condition is acne, acne scars, rosacea, a vascular lesion, a tattoo, or a nevus selected from Becker's nevus, blue nevus, congenital nevus, pigmented nevus, nevus of Ota and Ito, pigmented spindle cell nevus, and dysplastic nevus; and a vascular lesion selected from matted telangiectasia, lentigines, cherry angioma, spider angioma, vascular birthmarks, blue port wine stain, red port wine stain, purple port wine stain, red facial vein, blue facial vein, red leg vein, and blue leg veins. 
tretiranje navedenog stanja kože aktiničnom svjetlošću tijekom vremena koje je dovoljno da navedeni fotoaktivator izazove aktivaciju navedenog oksidansa, gdje stanje kože je odabrano od akni, ožiljaka od akni, rozacee, nevusa odabranog od Beker-ovog nevusa, plavog nevusa, kongenitalnog nevusa, pigmentnog nevusa, Ota nevusa i Ito nevusa, pigmentnog nevusa vretenastih stanica, i displastičnog nevusa; i krvožilne lezije odabrane od mrežaste telangiektazije, lentigines-a, angioma nalik trešnji (cherry angioma), paukolikih angioma, krvožilnih biljega od rođenja, plave „port wine„ mrlje (blue port wine stain), crvene „port wine“ mrlje (red port wine stain), ljubičaste „port wine“ mrlje (purple port wine stain), crvene vene lica, plave vene lica, crvene vene noge, i plavih vena noge;
Green wood or other wood that may be used in the process according to the invention and that is sawn into board-like, plane pieces of wood may have a humidity of approximately 80 %. 
Zeleno drvo ili drugo drvo koje se može koristiti u postupku koji je u skladu s ovim izumom, i koje je ispiljeno u ravne komade drva koji imaju oblik ploče, mogu imati vlažnost od približno 80 %.
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the density of the extended release matrix formulation is equal to or less than about 1.20 g/cm3 preferably equal to or less than about 1.19 g/cm3. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da je gustoća formulacije matrice sa produljenim otpuštanjem jednaka ili manja od oko 1.20 g/cm3 poželjno jednaka ili manja od oko 1.19 g/cm3.
The crystalline form of claim 1, wherein the crystalline form has an X-Ray powder diffraction (XRPD) pattern substantially the same as shown in FIG. 2 . 
Kristalni oblik prema bilo kojem od zahtjeva 1-3, naznačen time da navedeni kristalni oblik ima spektar difrakcije X-zraka praha (XRPD) isti kao što je prikazan na Slici 2.
Target pathogen object of the assay: 
Datum objave europskog patenta:
The unsaturated compounds are preferably polyunsaturated compounds; it is also preferred that the composition has a content of oligomeric impurities lower than 30% by weight, in particular lower than 15% by weight. 
Poželjno je da pripravak ima sadržaj oligomernih onečišćenja niži od 30 % po masi, naročito niži od 15 % po masi.
Principle Asenapine maleate of the orthorhombic form was mixed into a gelatin/mannitol matrix and dosed by weight into pre-formed pockets. 
Princip Asenapin maleat ortorombskog oblika pomiješan je u želatinsko/manitolni matriks i doziran prema težini u prethodno oblikovane odjeljke.
According to a further embodiment, the water insoluble or hydrophobic constituent comprises oily substances, fatty acids or proteins, which are either originally present in the beverage or alternatively added to the beverage. 
Napitak u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje navedeni sastojak koji nije topiv u vodi ili je hidrofobičan sadrži uljne supstance, masne kiseline ili proteine koji su ili originalno prisutni u napitku ili alternativno dodati napitku.
is an optionally substituted heteroaryl or an optionally substituted 8 to 14 membered aryl; 
Rs je opcijski supstituirani heteroaril ili opcijski supstituirani 8 do 14-člani aril;
An oral immediate release pharmaceutical composition of claim 4, wherein the formulation comprises an amount of oxycodone or a pharmaceutically acceptable salt thereof equivalent to 2.5 mg to 40 mg of oxycodone hydrochloride and an amount of naloxone or a pharmaceutically acceptable salt thereof equivalent to 1.25 mg to 20 mg of naloxone hydrochloride. 
Oralni farmaceutski sastav s trenutnim oslobađanjem prema zahtjevu 4, pri čemu formulacija sadrži količinu oksikodona ili njegove farmaceutski prihvatljive soli ekvivalentnu 2,5 mg do 40 mg oksikodon hidroklorida i količinu naloksona ili njegove farmaceutski prihvatljive soli ekvivalentnu 1,25 mg do 20 mg nalokson hidroklorida.
The composition for use in a method according to any one of claims 8-10 wherein the composition is for administration via an intradermal, mucosal, intramuscular, subcutaneous, sublingual, rectal, or vaginal route. 
Smjesa za upotrebu u metodi prema bilo kojem od patentnih zahtjeva 8-10, naznačena time, što je smjesa namijenjena za primjenu intradermalnim, mukoznim, intramuskularnim, supkutanim, sublingvalnim, rektalnim ili vaginalnim putem.
Device according to claim 1, wherein the echo-sounder and/or the GPS system and/or the camera system is arranged on the controllable floating body and is connected to the drive unit of the caterpillar chassis and a controller therefor. 
Uređaj sukladno bilo kojem od zahtjeva 1 do 15, naznačen time što je dubinomjer (26) i/ili GPS sustav i/ili sustav kamere organiziran na plutajućem tijelu koje je moguće kontrolirati i spojen je na pogonsku jedinicu šasije gusjeničara (10) i kontroler je iste.
After 12 h the solvent was evaporated off, the residue was dissolved in 40 ml of DCM and the organic phase was washed with brine (20 ml) and dried over Na2SO4. 
Otapalo je upareno nakon 12 h, ostatak je otopljen u 40 mL DCM 1 organska faza je prana otopinom soli (20 mL) i sušena iznad Na,SOx.
A compound of Formula (I): wherein: 
Spoj, naznačen time, da je spoj Formule (I) gdje:
When in this specification reference is made to a (I-4C)alkyl group it is to be understood that such groups refer to alkyl groups containing up to 4 carbon atoms. 
Kada se u ovoj specifikacji navodi (1-4C)alkilna skupina, podrazumijeva se da se takve skupine odnose na alkilne skupine koje sadržavaju do 4 ugljikova atoma.
The pharmaceutical composition according to claim 8 or 9, comprising additional 5-HT7-active components selected from the group comprising aripiprazole, amisulpride, chlorpromazine, clozapine, risperidone, ziprasidone, fluoxetine, 5-CT, 5-methoxytryptamine, 8-OH-DPAT, aripiprazole, AS-19, E-55888, MSD-5a, LP-12, LP-44, LP-211, RA-7, and Nw -methylserotonin. 
7. = Farmaceutski pripravak za uporabu prema zahtjevu 5 ili 6, naznačen time što sadrži dodatne 5-HT;. aktivne komponente odabrane iz skupine koja sadrži aripiprazol, amisulprid, klorpromazin, klozapin, risperidon, ziprasidon, fluoksetin, 5-CT, 5-metoksitriptamin, 8 -OH-DPAT, aripiprazol, A$S-19, E-55888, MSD-5a, LP-12, LP-44, LP-211, RA-7 i N*-metilserotonin.
A developer supply container according to Claim 14, wherein said drive converting portion (2d, 3b) converts the rotational force so that when said partition (17) is in the closing position, a suction action through said discharge opening (3a) is carried out by said pump portion (2b). 
HR P20180544 T1 gdje navedeni dio za pretvorbu pogona (2d, 3b) pretvara silu vrtnje na takav način da u najmanju ruku kada je navedena pregrada (17) u zatvorenom položaju, gdje navedeni crpni dio (2b) vrši pražnjenje kroz navedeni otvor za ispuštanje (34).
The antenna may be adapted to transmit the fields/signals from the inside of the packaging to the outside. 
Antena se može prilagoditi za odašiljanje polja/signala iz unutarnje strane pakiranja prema van.
selecting said cancer for treatment with the specific binding member if the HER2 gene copy number is greater than or equal to 10 per tumour cell. 
(ii) odabiranje spomenutog pacijenta za liječenje sa specifičnim veznim elementom ako je prosječan broj genskih kopija od HER2 veći od 10 ili je točno 10 po stanici tumora.
a particle comprising an opioid antagonist dispersed in a melt-extruded matrix, wherein the matrix comprises one or more pharmaceutically acceptable first hydrophobic materials; and a layer of second hydrophobic material coated on the particle in an amount of 2% to 30% by weight, based on the weight of the particle. The pharmaceutical oral dosage form according to claim 1, wherein the layer of second hydrophobic material is coated on the particle in an amount of 2% to 30% by weight, based on the weight of the particle. 
prvo mnoštvo ekstrudiranih čestica koje sadrže nepovoljni agens disperziran u matriksu i sloj koji pokriva najmanje dio ekstrudiranih čestica, gdje matriks sadrži prvi hidrofobni materijal i sloj sadrži drugi hidrofobni materijal; i drugo mnoštvo farmaceutski prihvatljivih čestica koje sadrže aktivni agens disperziran u matriksu, gdje matriks sadrži treći hidrofobni materijal, naznačen time da matriks i sloj prvog mnoštva čestica odvajaju nepovoljni agens u čistom obliku za doziranje.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
wherein the compound of formula (I) is present in an amount within the range of from 1% to 80% by weight; 
pri čemu spoj formule (I) je zastupljen u količini u rasponu od 1% do 80% po masi;
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound fludioxonil. 
spoja formule (I) [image] naznačen time da R1 je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i spoj mandipropamid.
The compound according to any one of claims 10-11, for use as medicament. The compound according to claims 10-11 for use according to claim 13, characteized in that it is used as anti-cancer medicament. 
Spoj u skladu s patentnim zahtjevima 10-11 za uporabu u skladu s patentnim zahtjevom 13, naznačen time, da se koristi kao lijek za liječenje raka.
In a particular embodiment, the reaction is performed at a temperature between about −10° C. and about −80° C. in an ether for between about 12 and about 20 hours, particularly for about 16 hours. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se reakcija odvija na temperaturi između približno 10 "C do približno -80 *C u eteru između približno 12 do približno 20 sati. 3.
A peptide comprising the amino acid sequence of SEQ ID NO: 30. 
Peptid koji sadrži aminokiselinsku sekvencu bilo koje od SEQ ID NO: 24, 25 ili 26.
<400> 80 An antibody or fragment thereof which binds human a-synuclein protofibrils having a molecular weight in a range of from 1000 to 5000 kDa, wherein binding of the antibody or fragment to each of a-synuclein monomers and B-synuclein monomers is at least 100 times less than binding of the antibody or fragment to human a-synuclein protofibrils, the antibody or fragment having three variable heavy (VH) CDR sequences (VH-CDR-1, VH-CDR-2, and VH-CDR-3) and three variable light (VL) CDR sequences (VL-CDR-1, VL-CDR-2, and VL-CDR-3), and wherein the the antibody or fragment thereof has a CDR sequence combination selected from the following combinations: 
Protutijelo, ili njegov fragment, naznačeno time što se veže na ljudski a-sinukleinski protofibrili molekulske težine u rasponu od 1000 do 5000 kDa, gdje vezanje protutijela, ili fragmenta, na svaki od a-sinukleinskih monomera i f-sinukleinskih monomera je najmanje 100 puta slabije od vezanja protutijela, ili fragmenta, na ljudske a-sinukleinske protofibrile, gdje protutijelo, ili fragment, ima tri varijabilna teška (VH) CDR slijeda (VH- CDR-1, VH-CDR-2, te VH-CDR-3) i tri varijabilna laka (VL) CDR slijeda (VL-CDR-1, VL-CDR-2, te VL-CDR3), te gdje protutijelo, ili njegov fragment, ima kombinacija CDR sljedova koju se bira između sljedećih kombinacija:
The production method according to claim 1, wherein the metal ion is provided in the form of chloride, bromide, nitrate, sulfate or acetate of the metal. 
Postupak proizvodnje u skladu s patentnim zahtjevom 1, naznačen time, da je metalni ion u obliku klorida, bromida, nitrata, sulfata ili acetata metala.
The nucleic acid of claim 1, wherein the IGF-II peptide tag comprises amino acids 8-67 of SEQ ID NO: 5 except for a mutation at the amino acid position corresponding to position 37 of SEQ ID NO: 5. 
Ciljani terapeutski fuzijski protein prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da razmaknica sadrži sekvencu aminokiseline Gly-Ala-Pro (GAP) (SEQ ID NO: 9) ili Gly-Pro-Ser (GPS) (SEQ ID NO: 10).